N-isopropyl-(1S)-1-phenylpropylamine | 1120341-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-isopropyl-(1S)-1-phenylpropylamine
• 英文别名: (1S)-1-phenyl-N-propan-2-ylpropan-1-amine
• CAS: 1120341-20-9
• 化学式: C₁₂H₁₉N
• 分子量: 177.29
• InChiKey: UIRHNVZMIFRCLF-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-isopropyl-(1S)-1-phenylpropylamine 、 palladium dichloride 在 LiCl 、 NaOAc 作用下， 以 甲醇 为溶剂， 生成 tris-μ-chloro-tris[N-isopropyl-(1S)-1-phenylpropylamine-2C,N]tripalladium(II)
  参考文献：
  名称：

  Chiral Ligands to Support Self-Assembly of [LPdCl]₃ Trimers via a Set of Secondary Interactions

  摘要：

  Novel [LPdCl](3) trimers (L = chiral secondary benzylamine) were synthesized via direct cyclopalladation. The structures of trimeric palladacycles were confirmed by means of X-ray analysis. The secondary interactions stabilizing trimeric molecules were investigated. An equilibrium between dimeric and trimeric palladacycle species was found in solution by means of dynamic NMR- spectroscopy and ESI mass spectrometry study.

  DOI：

  10.1021/om8006695

文献信息

• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170190689A1

  公开（公告）日：2017-07-06

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了化合物I的化合物，或其药用盐，其调节磷脂酰肌醇3-激酶-γ（PI3Kγ）的活性，并且在治疗与PI3Kγ活性相关的疾病方面具有用途，例如自身免疫疾病、癌症、心血管疾病和神经退行性疾病。
• THYROID RECEPTOR LIGANDS
  申请人：Ryono Denis E.

  公开号：US20100298276A1

  公开（公告）日：2010-11-25

  Thyroid receptor ligands are provided which have the general formula I wherein: R 1 is R 2 and R 3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R 2 and R 3 is other than hydrogen; R 4 is R 5 and R 6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R 7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R 8 is aryl, heteroaryl, or cycloalkyl; R 9 is R 7 or hydrogen; R 10 is hydrogen, halogen, cyano or alkyl; R 11 and R 12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R 13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R 14 and R 15 may be the same or different and are selected from hydrogen and alkyl, or R 14 and R 15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R 16 is hydrogen or alkyl of 1 to 4 carbons; R 17 and R 18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO 2 —), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

  提供了甲状腺受体配体，其具有一般公式I，其中：R1为R2和R3，R2和R3相同或不同，为氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，但至少其中一个为非氢；R4为R5和R6，R5和R6相同或不同，选择自氢、芳基、杂环芳基、烷基、环烷基、芳基烷基或杂环芳基；R7为芳基、杂环芳基、烷基、芳基烷基或杂环芳基；R8为芳基、杂环芳基或环烷基；R9为R7或氢；R10为氢、卤素、氰基或烷基；R11和R12各自独立选择自氢、卤素、烷氧基、羟基（—OH）、氰基和烷基；R13为羧酸（COOH）或其酯、膦酸和膦酸酯、磺酸、四唑、羟胺酸、噻唑二酮、酰基磺胺或艺术中已知的其他羧酸替代物；R14和R15可相同或不同，选择自氢和烷基，或R14和R15可结合形成2至5个亚甲基组成的链[—(CH2)m-，m=2、3、4或5]，从而形成3至6成员的环烷基环；R16为氢或1至4个碳原子的烷基；R17和R18相同或不同，选择自氢、卤素和烷基；n为0或1至4的整数；X为氧（—O—）、硫（—S—）、砜基（—SO2—）、砜基（—SO—）、硒（—Se—）、羰基（—CO—）、氨基（—NH—）或亚甲基（— -）；其中取代基如上述所述。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或障碍，其中上述化合物以治疗有效剂量给予。
• Dpp-iv inhibitors
  申请人：Edwards John Paul

  公开号：US20070197522A1

  公开（公告）日：2007-08-23

  The invention relates to compounds of formula (I) Z-C(R 1 R 2 )—C(R 3 NH 2 )—C(R 4 R 5 )—X—N(R 6 R 7 )  (I), wherein Z, R 1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式（I）的化合物：Z-C（R1R2）-C（R3NH2）-C（R4R5）-X-N（R6R7）（I），其中Z，R1-7和X的含义如所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及其作为药物的生产和使用。
• GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
  申请人：NEUROCRINE BIOSCIENCES, INC.

  公开号：EP1255738B1

  公开（公告）日：2012-03-07
• US7557143B2
  申请人：——

  公开号：US7557143B2

  公开（公告）日：2009-07-07